Squarepoint’s Juno Therapeutics, Inc. JUNO Stock Holding History

Squarepoint’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-16,859	Closed	-$771K	–	2457
2017 Q4	$771K	Sell	16,859 -100,324	-86%	-$5M	0.01%	952
2017 Q3	$5.26M	Buy	117,183 +90,278	+336%	+$3.08M	0.1%	257
2017 Q2	$804K	Buy	+26,905	New	+$664K	0.02%	788
2016 Q1	–	Sell	-12,700	Closed	-$558K	–	1611
2015 Q4	$558K	Buy	+12,700	New	+$630K	0.06%	480

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Squarepoint's JUNO Position: Q1 2018 in Review

Squarepoint sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 16,859 shares — an estimated $771K sold.

Squarepoint first reported a position in JUNO in Q4 2015 and held it in 4 quarters. The position peaked at $5.26M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Squarepoint reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Squarepoint sold 16,859 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $771K.
Squarepoint first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
Squarepoint's Juno Therapeutics, Inc. position peaked at $5.26M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Squarepoint's 13F filing for Q1 2018, filed 15 May 2018.